Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Lantheus ( (LNTH) ).
On April 30, 2026, Lantheus shareholders approved a series of corporate governance and compensation measures at the company’s annual meeting, including an amendment to declassify its board of directors over three years and to allow shareholders to remove directors with or without cause once declassification is complete. Investors also re-elected four Class II directors to terms expiring in 2029, endorsed executive pay on an advisory basis, opted for annual “say on pay” votes, approved the 2026 equity incentive plan, and ratified Deloitte & Touche LLP as auditor for the 2026 fiscal year, signaling broad shareholder support for the company’s governance and compensation framework.
The board declassification and enhanced removal rights mark a shift toward more shareholder-friendly governance at Lantheus, potentially increasing board accountability and aligning the company more closely with prevailing best practices in the public markets. Approval of the equity incentive plan and continued backing of executive compensation suggest investors are comfortable with management’s strategic direction and the use of equity-based awards to retain and motivate key executives, while auditor ratification reinforces confidence in the company’s financial oversight.
The most recent analyst rating on (LNTH) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Lantheus stock, see the LNTH Stock Forecast page.
Spark’s Take on LNTH Stock
According to Spark, TipRanks’ AI Analyst, LNTH is a Neutral.
The score is driven primarily by solid multi-year financial strength but a recent TTM slowdown in margins and cash-flow momentum. Technicals are supportive (price above key averages) yet overbought, increasing near-term risk. Valuation is a headwind with a ~31.8 P/E and no dividend yield, while the latest earnings call was neutral with near-term PYLARIFY pressure and 2027-weighted growth catalysts.
To see Spark’s full report on LNTH stock, click here.
More about Lantheus
Lantheus is a medical imaging and diagnostics company that develops, manufactures, and commercializes imaging agents and related products for use in detecting and managing disease. The company focuses on providing specialized radiopharmaceuticals and diagnostic solutions to hospitals, clinics, and imaging centers in the healthcare sector.
Average Trading Volume: 923,349
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.51B
Find detailed analytics on LNTH stock on TipRanks’ Stock Analysis page.